Antiphospholipid Antibodies Are Associated with an Increased Risk for Chronic Renal Insufficiency in Patients with Lupus Nephritis

Gabriella Moroni, Donatella Ventura, Paola Riva, Paola Panzeri, Silvana Quaglini, Giovanni Banfi, Paola Simonini, Rossella Bader, Pier Luigi Meroni, Claudio Ponticelli

Research output: Contribution to journalArticle

118 Citations (Scopus)

Abstract

Background: Previous studies have documented the high frequency of thrombosis and fetal loss in patients with lupus nephritis and antiphospholipid (aPL) antibodies, but there is little information on the impact of aPL antibodies on the outcome of lupus nephritis. The aims of this study are to evaluate the prevalence of aPL antibodies in patients with lupus nephritis and assess their prognostic value for thrombosis and pregnancy morbidity and impact on long-term renal outcome. Methods: One hundred eleven patients with lupus nephritis followed up for a mean of 173 ± 100 months were tested regularly for immunoglobulin G (IgG) and IgM anticardiolipin antibodies and lupus anticoagulant. Results: The overall prevalence of aPL antibodies was 26%. In follow-up, 79% of aPL antibody-positive patients experienced thrombotic events and/or fetal losses, and aPL antibodies were associated significantly with arterial or venous thrombosis (P = 0.00001), pregnancy morbidity (P = 0.045), thrombocytopenia (P = 0.0015), and persistent arterial hypertension (P = 0.028). aPL antibodies were significantly more frequent in patients with biopsy-proven membranous lupus nephritis (P = 0.01). A strong association between aPL antibodies and the development of chronic renal Insufficiency in the long-term outcome also was found (P = 0.01). With multivariate analysis, aPL antibody positivity (P = 0.02), high plasma creatinine level at presentation (P = 0.01), and chronicity index (P = 0.00004) were independent predictors of chronic renal function deterioration. Conclusion: Detection of aPL antibodies in patients with lupus nephritis is useful not only to identify patients at risk for vascular and obstetric manifestations, but also for their potential deleterious impact on renal outcome.

Original languageEnglish
Pages (from-to)28-36
Number of pages9
JournalAmerican Journal of Kidney Diseases
Volume43
Issue number1
DOIs
Publication statusPublished - Jan 2004

Fingerprint

Lupus Nephritis
Antiphospholipid Antibodies
Chronic Renal Insufficiency
Kidney
Thrombosis
Morbidity
Lupus Coagulation Inhibitor
Anticardiolipin Antibodies
Pregnancy
Venous Thrombosis
Thrombocytopenia
Obstetrics
Immunoglobulin M
Blood Vessels
Creatinine
Multivariate Analysis
Immunoglobulin G
Hypertension
Biopsy

Keywords

  • Antiphospholipid (aPL) antibodies
  • Arterial hypertension
  • Chronic renal insufficiency
  • Fetal loss
  • Lupus nephritis
  • Systemic lupus erythematosus (SLE)
  • Thrombosis

ASJC Scopus subject areas

  • Nephrology

Cite this

Antiphospholipid Antibodies Are Associated with an Increased Risk for Chronic Renal Insufficiency in Patients with Lupus Nephritis. / Moroni, Gabriella; Ventura, Donatella; Riva, Paola; Panzeri, Paola; Quaglini, Silvana; Banfi, Giovanni; Simonini, Paola; Bader, Rossella; Meroni, Pier Luigi; Ponticelli, Claudio.

In: American Journal of Kidney Diseases, Vol. 43, No. 1, 01.2004, p. 28-36.

Research output: Contribution to journalArticle

Moroni, Gabriella ; Ventura, Donatella ; Riva, Paola ; Panzeri, Paola ; Quaglini, Silvana ; Banfi, Giovanni ; Simonini, Paola ; Bader, Rossella ; Meroni, Pier Luigi ; Ponticelli, Claudio. / Antiphospholipid Antibodies Are Associated with an Increased Risk for Chronic Renal Insufficiency in Patients with Lupus Nephritis. In: American Journal of Kidney Diseases. 2004 ; Vol. 43, No. 1. pp. 28-36.
@article{03bad7623ce044238dbe3331569cd1b8,
title = "Antiphospholipid Antibodies Are Associated with an Increased Risk for Chronic Renal Insufficiency in Patients with Lupus Nephritis",
abstract = "Background: Previous studies have documented the high frequency of thrombosis and fetal loss in patients with lupus nephritis and antiphospholipid (aPL) antibodies, but there is little information on the impact of aPL antibodies on the outcome of lupus nephritis. The aims of this study are to evaluate the prevalence of aPL antibodies in patients with lupus nephritis and assess their prognostic value for thrombosis and pregnancy morbidity and impact on long-term renal outcome. Methods: One hundred eleven patients with lupus nephritis followed up for a mean of 173 ± 100 months were tested regularly for immunoglobulin G (IgG) and IgM anticardiolipin antibodies and lupus anticoagulant. Results: The overall prevalence of aPL antibodies was 26{\%}. In follow-up, 79{\%} of aPL antibody-positive patients experienced thrombotic events and/or fetal losses, and aPL antibodies were associated significantly with arterial or venous thrombosis (P = 0.00001), pregnancy morbidity (P = 0.045), thrombocytopenia (P = 0.0015), and persistent arterial hypertension (P = 0.028). aPL antibodies were significantly more frequent in patients with biopsy-proven membranous lupus nephritis (P = 0.01). A strong association between aPL antibodies and the development of chronic renal Insufficiency in the long-term outcome also was found (P = 0.01). With multivariate analysis, aPL antibody positivity (P = 0.02), high plasma creatinine level at presentation (P = 0.01), and chronicity index (P = 0.00004) were independent predictors of chronic renal function deterioration. Conclusion: Detection of aPL antibodies in patients with lupus nephritis is useful not only to identify patients at risk for vascular and obstetric manifestations, but also for their potential deleterious impact on renal outcome.",
keywords = "Antiphospholipid (aPL) antibodies, Arterial hypertension, Chronic renal insufficiency, Fetal loss, Lupus nephritis, Systemic lupus erythematosus (SLE), Thrombosis",
author = "Gabriella Moroni and Donatella Ventura and Paola Riva and Paola Panzeri and Silvana Quaglini and Giovanni Banfi and Paola Simonini and Rossella Bader and Meroni, {Pier Luigi} and Claudio Ponticelli",
year = "2004",
month = "1",
doi = "10.1053/j.ajkd.2003.09.011",
language = "English",
volume = "43",
pages = "28--36",
journal = "American Journal of Kidney Diseases",
issn = "0272-6386",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - Antiphospholipid Antibodies Are Associated with an Increased Risk for Chronic Renal Insufficiency in Patients with Lupus Nephritis

AU - Moroni, Gabriella

AU - Ventura, Donatella

AU - Riva, Paola

AU - Panzeri, Paola

AU - Quaglini, Silvana

AU - Banfi, Giovanni

AU - Simonini, Paola

AU - Bader, Rossella

AU - Meroni, Pier Luigi

AU - Ponticelli, Claudio

PY - 2004/1

Y1 - 2004/1

N2 - Background: Previous studies have documented the high frequency of thrombosis and fetal loss in patients with lupus nephritis and antiphospholipid (aPL) antibodies, but there is little information on the impact of aPL antibodies on the outcome of lupus nephritis. The aims of this study are to evaluate the prevalence of aPL antibodies in patients with lupus nephritis and assess their prognostic value for thrombosis and pregnancy morbidity and impact on long-term renal outcome. Methods: One hundred eleven patients with lupus nephritis followed up for a mean of 173 ± 100 months were tested regularly for immunoglobulin G (IgG) and IgM anticardiolipin antibodies and lupus anticoagulant. Results: The overall prevalence of aPL antibodies was 26%. In follow-up, 79% of aPL antibody-positive patients experienced thrombotic events and/or fetal losses, and aPL antibodies were associated significantly with arterial or venous thrombosis (P = 0.00001), pregnancy morbidity (P = 0.045), thrombocytopenia (P = 0.0015), and persistent arterial hypertension (P = 0.028). aPL antibodies were significantly more frequent in patients with biopsy-proven membranous lupus nephritis (P = 0.01). A strong association between aPL antibodies and the development of chronic renal Insufficiency in the long-term outcome also was found (P = 0.01). With multivariate analysis, aPL antibody positivity (P = 0.02), high plasma creatinine level at presentation (P = 0.01), and chronicity index (P = 0.00004) were independent predictors of chronic renal function deterioration. Conclusion: Detection of aPL antibodies in patients with lupus nephritis is useful not only to identify patients at risk for vascular and obstetric manifestations, but also for their potential deleterious impact on renal outcome.

AB - Background: Previous studies have documented the high frequency of thrombosis and fetal loss in patients with lupus nephritis and antiphospholipid (aPL) antibodies, but there is little information on the impact of aPL antibodies on the outcome of lupus nephritis. The aims of this study are to evaluate the prevalence of aPL antibodies in patients with lupus nephritis and assess their prognostic value for thrombosis and pregnancy morbidity and impact on long-term renal outcome. Methods: One hundred eleven patients with lupus nephritis followed up for a mean of 173 ± 100 months were tested regularly for immunoglobulin G (IgG) and IgM anticardiolipin antibodies and lupus anticoagulant. Results: The overall prevalence of aPL antibodies was 26%. In follow-up, 79% of aPL antibody-positive patients experienced thrombotic events and/or fetal losses, and aPL antibodies were associated significantly with arterial or venous thrombosis (P = 0.00001), pregnancy morbidity (P = 0.045), thrombocytopenia (P = 0.0015), and persistent arterial hypertension (P = 0.028). aPL antibodies were significantly more frequent in patients with biopsy-proven membranous lupus nephritis (P = 0.01). A strong association between aPL antibodies and the development of chronic renal Insufficiency in the long-term outcome also was found (P = 0.01). With multivariate analysis, aPL antibody positivity (P = 0.02), high plasma creatinine level at presentation (P = 0.01), and chronicity index (P = 0.00004) were independent predictors of chronic renal function deterioration. Conclusion: Detection of aPL antibodies in patients with lupus nephritis is useful not only to identify patients at risk for vascular and obstetric manifestations, but also for their potential deleterious impact on renal outcome.

KW - Antiphospholipid (aPL) antibodies

KW - Arterial hypertension

KW - Chronic renal insufficiency

KW - Fetal loss

KW - Lupus nephritis

KW - Systemic lupus erythematosus (SLE)

KW - Thrombosis

UR - http://www.scopus.com/inward/record.url?scp=9144234103&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=9144234103&partnerID=8YFLogxK

U2 - 10.1053/j.ajkd.2003.09.011

DO - 10.1053/j.ajkd.2003.09.011

M3 - Article

C2 - 14712424

AN - SCOPUS:9144234103

VL - 43

SP - 28

EP - 36

JO - American Journal of Kidney Diseases

JF - American Journal of Kidney Diseases

SN - 0272-6386

IS - 1

ER -